Abcam plc ABCM
Day range unavailable
52-week range unavailable
- Market cap
- 5.52B
- Revenue (ttm)
- 379.70M
- Profit margin
- 0.66%
- Shares out
- 230.15M
- Beta
- 0.86
- Analysts
- Hold
- Price target
- 1,902.05 (+7828.5%)
- Earnings date
- Mar 20, 2023
Key statistics
- Enterprise value
- 5.64B
- PEG ratio
- 0.00
- Price / sales
- 14.54
- Price / book
- 7.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 9.70%
- Free cash flow
- 28.94M
- Total cash
- 79.00M
- Total debt
- 217.00M
- Return on equity
- 0.35%
- Short % of float
- 0.00%
- 50-day average
- 23.39
- 200-day average
- 20.52
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Mar 20, 2023
Expected Mar 20, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 20, 2023 | Dec 1, 2022 | 0.19 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 8, 2023 | RBC Capital | reit | Sector Perform | Sector Perform |
| Aug 29, 2023 | SVB Leerink | down | Outperform | Market Perform |
| Aug 21, 2023 | RBC Capital | reit | Sector Perform | Sector Perform |
| Jun 19, 2023 | RBC Capital | down | Outperform | Sector Perform |
| Jun 15, 2023 | B of A Securities | up | Neutral | Buy |
| Jun 11, 2023 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Abcam plc
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam plc operates as a subsidiary of Danaher Corporation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- abcam.com
News
Molecular Instruments and Abcam Announce Broad Compatibility of the HCR™ HiFi Encoder with Abcam's Best-in-Class RabMAb® and Mouse Antibody Portfolio 
Metabolism Assays Market Size Projected to Reach USD 3.1 Billion by 2034, Growing Steadily at 6.7% CAGR | Report by Transparency Market Research, Inc 
Danaher completes $5.7 billion acquisition of Abcam 
Danaher Completes Acquisition of Abcam 
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales 
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign 
Jonathan Milner Issues Statement Responding to the Glass Lewis Report 
Jonathan Milner Issues Statement Responding to ISS Report 
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company 
Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short
Your note
Sign in to keep a note on ABCM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Baldock (Michael Shaun) | — | Bought | Mar 15, 2022 | 10,910 |
| Crawford (Sally) | — | Bought | Apr 28, 2022 | 15,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Durable Capital Partners Lp | 6.27% | 14,372,447 | 351.69M | Jun 29, 2023 |
| Wellington Management Group, LLP | 5.97% | 13,692,349 | 335.05M | Jun 29, 2023 |
| Harding Loevner LLC | 4.66% | 10,687,444 | 261.52M | Jun 29, 2023 |
| Brown Capital Management, LLC | 4.34% | 9,955,641 | 243.61M | Jun 29, 2023 |
| Baillie Gifford and Company | 3.56% | 8,152,052 | 199.48M | Jun 29, 2023 |
| Point72 Asset Management, L.P. | 3.46% | 7,933,976 | 194.14M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Specialized-Health Care Fund | 3.12% | 7,161,997 | 167.88M | Jul 30, 2023 |
| Brown Capital Management International Small Company Fund | 2.76% | 6,320,253 | 154.66M | Jun 29, 2023 |
| Fidelity Select Portfolios - Medical Technology & Devices Port | 1.48% | 3,400,000 | 54.91M | May 30, 2023 |
| Alger Small Cap Focus Fund | 1.47% | 3,359,839 | 78.75M | Jul 30, 2023 |
| Price (T.Rowe) Small Cap Stock Fund | 1.31% | 3,013,538 | 73.74M | Jun 29, 2023 |
| Neuberger & Berman Genesis Fund | 1.18% | 2,696,265 | 65.98M | Jun 29, 2023 |